⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447226 | 0.83 | — | — | |
| SCHEMBL4070914 | 0.81 | POLB (0.44) | — | |
| SCHEMBL3043384 | 0.81 | POLB (0.44) | — | |
| SCHEMBL9952157 | 0.79 | GRIA1 (0.43) | — | |
| SCHEMBL8612225 | 0.76 | TSHR (0.43) | — | |
| SCHEMBL15259106 | 0.76 | ALDH1A1 (0.34) | — | |
| SCHEMBL12090531 | 0.75 | POLB (0.52) | — | |
| SCHEMBL1934672 | 0.75 | — | — | |
| SCHEMBL1145734 | 0.75 | CA1 (0.50) | — | |
| SCHEMBL147224 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | claimed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | claimed |
| EP-3038622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-07-06 | — | — | EP | claimed |
| WO-2015031650-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | CHAKRAVARTY SARVAJIT (US) | 2015-03-05 | — | — | WO | claimed |
| WO-2013186612-A1 | THE USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BET (BROMODOMAIN AND EXTRA TERMINAL DOMAIN) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-12-19 | — | — | WO | claimed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | claimed |
| EP-2488503-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | Myrexis, Inc. (US) | 2012-08-22 | — | — | EP | claimed |
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | claimed |
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | claimed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| WO-2003059279-A2 | EFFICIENT LIPOSOMAL ENCAPSULATION UNDER MILD CONDITIONS | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | claimed |
| WO-2003007085-A1 | SULFOXIDE PYROLID(IN)ONE ALKANOLAMINE STRIPPING AND CLEANING COMPOSITION | EKC TECHNOLOGY, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-6391901-B1 | Thrombin inhibitors | ELI LILLY AND COMPANY | 2002-05-21 | — | — | US | claimed |